Skip to main content
. Author manuscript; available in PMC: 2014 Aug 25.
Published in final edited form as: Leukemia. 2011 Mar 15;25(7):1174–1181. doi: 10.1038/leu.2011.43

Figure 4. CCR1 mediates at least partially CCL3 inhibitory effects on OBs.

Figure 4

(A) Western blot detection of pERK and ERK signaling in HS27A-derived OB treated with CCL3 in the presence of a small molecule CCR1 inhibitor (50 nM). (B) Osterix gene expression by quantitative PCR in OB treated for 4 hours with CCL3 with or without the CCR1 inhibitor (50 nM) (left panel) or MEK1 ihibitor, PD098059 (30 μM, 1h pretreatment) (right panel). (C) Osteocalcin gene expression by quantitative PCR in OB treated for 24 hours with CCL3 with or without the CCR1 inhibitor (50 nM) (* p<0.05).